World Preclinical Congress (WPC)
The World Preclinical Congress (WPC) is now a part of World Pharma Week, which takes place June 17–20, 2019 in Boston, MA. WPC gathers research, clinical, and industry experts to exchange expertise and opinions in the areas of disease modeling, drug metabolism and toxicity, target ID and validation, preclinical immuno-oncology, and translational CNS research. Takara Bio is excited to be attending WPC 2019 and giving a talk on our solutions for human hepatocyte differentiation and culture.
We're looking forward to seeing you at WPC. In the meantime, we invite you to review our technical notes and reach out to our scientists with any questions or requests via the "talk to a scientist" link below.
WPC 2019: Talk
Industrial-Scale Generation of Human iPSC-Derived Hepatocytes for Liver-Disease and Drug Development Studies
To realize the full potential of human pluripotent stem cells (hPSC) in regenerative medicine, disease modeling, and drug discovery, optimized culture conditions are required that allow homogeneous populations of undifferentiated stem cells to be generated followed by directed differentiation into preferred cell types of interest in a robust and predictable manner. We have previously developed an optimized hPSC culture system, called the Cellartis DEF-CS culture system, that enables noncolony, monolayer culture of hPSC and results in highly pluripotent cells that exhibit low spontaneous differentiation and stable karyotypes. These cells provide a rapidly renewable source of hPSC that are highly amenable to downstream differentiation into a variety of disease relevant cell types.
Using an optimized protocol that combines DEF-CS media, supplements, and coating reagents optimized for 2D monolayer culture, we have developed a standardized workflow that mimics embryonic development and allows for highly efficient differentiation of hPSC to definitive endoderm and further differentiation into hepatocytes. We will describe the creation of large panels of industrial-scale hPSC-derived hepatocytes with specific genotypes and phenotypes and their utility for drug metabolism and disease modeling. We will also demonstrate that the novel hepatocyte maintenance medium developed for our cryopreserved hPSC-derived hepatocytes also maintains the viability of cryopreserved human primary hepatocytes for over 4 weeks in culture, which is in sharp contrast to existing hepatocyte maintenance media available on the market today. The increased assay window for both functional hPSC-derived and human primary hepatocytes in 2D cultures represents an important step toward advancing the discovery of new treatments for metabolic disease, reducing the incidence of drug-induced liver injury, and developing new strategies for liver regeneration and transplantation.
Learn about an advancement in modeling metabolic disease with Cellartis enhanced hiPS-hepatocytes.
Learn how hiPS cell-derived hepatocytes with a 14-day assay window can support drug metabolism studies.
Cellartis Power Primary HEP Medium—a breakthrough solution for long-term intrinsic clearance studies of low-clearance drugs
View data for maintaining viable, functional human primary hepatocytes for up to four weeks.
See data on how to easily and consistently create your own hepatocytes.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2019 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.